Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
A legfontosabb adatok
- Ki végzi
- National Cancer Institute (NCI)
- Hol
- Tamuning (Guam)A helyszín megnézéseMég 1 másik országban, 1150 helyszínen
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 1210 fő, tervezett
- Kezdés
- 2020. jún. 16.
- Várható befejezés
- 2030. jan. 31.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Biospecimen Collection
- Carboplatin
- Cisplatin
- Computed Tomography
- Echocardiography Test
- Gemcitabine Hydrochloride
- Magnetic Resonance Imaging
- Observation Activity
- Paclitaxel
- Pembrolizumab
- Pemetrexed Disodium
- Questionnaire Administration
- A regiszteradat frissítve
- 2026. november 12.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan felnőtteket keres, akiknek a IIA, IIB, IIIA vagy IIIB stádiumú nem kissejtes tüdőrákját műtéttel teljesen eltávolították. A szokásos kemoterápia mellé pembrolizumabot adnak.
- Életkor
- 18 éves vagy idősebb
- Nem
- Nemtől függetlenül csatlakozhat bárki.
- A betegség stádiuma
- Nem kissejtes tüdőrák (laphámsejtes vagy nem laphámsejtes), IIA, IIB, IIIA vagy IIIB (T3-4N2) stádium, teljesen eltávolítva, negatív műtéti szélekkel (R0). A stádium besorolása az AJCC 8. kiadása szerint történik. A csak műtét után kiderült N2 betegség megengedett.
- Korábbi kezelés
- A műtét előtt vagy után nem kaphatott kemoterápiát vagy más kezelést erre a tüdőrákra. A regisztráció a műtét után 30-77 nappal történhet, a műtétből teljesen felépülve. A regisztráció előtti 30 napban nem kaphatott élő vakcinát.
- Biomarker vagy leletérték
- Helyi vizsgálati eredmények kellenek: nincs EGFR exon 19 deléció vagy EGFR L858R mutáció, és nincs ALK átrendeződés (csak nem laphámsejtes esetben). PD-L1 vizsgálat a DAKO 22C3, DAKO 28-8, EIL3N vagy SP263 módszerek egyikével.
A részvétel fő kizáró okai
- A műtét előtt már ismert N2 betegség
- Korábbi szilárdszerv- vagy allogén szövetátültetés
- Aktív autoimmun betegség, amelyet az elmúlt 2 évben szisztémásan kezeltek
- Terhesség vagy szoptatás; ismert hepatitis C vagy korábbi hepatitis B
- Aktív második daganat, vagy szteroidot igénylő tüdőgyulladás (pneumonitis)
A regiszter feltételei, szó szerint
Mind a 25 feltétel megnézéseKevesebb
Ki vehet részt
- A female of childbearing potential is a sexually mature female who:; Has not undergone a hysterectomy or bilateral oophorectomy; or; Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)
- Local testing of EGFR with no EGFR exon 19 deletion or EGFR L858 R mutation (applicable to non-squamous patients only)
- Local testing of ALK with no ALK rearrangement (failed testing is considered negative) (applicable to non-squamous patients only)
- Local testing of PD-L1 immunohistochemistry (IHC) using one of the following assays: DAKO 22C3, DAKO 28-8, EIL3N or SP263
- Completely resected stage IIA, IIB IIIA or IIIB (T3-4N2) non-small cell lung cancer (NSCLC) (squamous or non-squamous) with negative margins (complete R0 resection). Patients will be staged according to the 8th edition of the American Joint Committee on Cancer (AJCC) Staging Manual, 2017; Note: Patients with pathologic N2 disease, completely resected, are eligible. However, patients known to have N2 disease prior to surgery are not eligible; guidelines do not recommend up-front surgery for this population
- Complete recovery from surgery. Registration to A081801 must be 30-77 days following surgery
- No prior neoadjuvant or adjuvant therapy for current lung cancer diagnosis
- No prior allogeneic tissue/solid organ transplant
- Patients must NOT have uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, unstable angina pectoris, that would limit compliance with study requirements
- No current pneumonitis or history of (non-infectious) pneumonitis that required steroids
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0-1
- No active auto-immune disease that has required systemic treatment within the last 2 years (e.g., disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid release therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment
- Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects; Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required
- No patients with a "currently active" second malignancy that is progressing or has required active treatment within the last 3 years. Participants with non-melanoma skin cancers, low grade or low-risk cancers, or stage I malignancies not requiring systemic therapy (e.g., prostate cancer requiring only observation or superficial bladder cancer), or carcinoma in situ (e.g., breast carcinoma or cervical cancer in situ) that have undergone potentially curative therapy are eligible
- No hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients
- No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist) are live attenuated vaccines and are not allowed
- No known hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection or known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive)
- Absolute neutrophil count (ANC) >= 1,500/mm\^3
- Platelet count >= 100,000/mm\^3
- Hemoglobin >= 8 gm/dl
- Calculated (Calc.) creatinine clearance >= 45 mL/min
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Helyszínek itt: Guam
Még 1 másik országban, 1150 helyszínen
- FHP Health Center-GuamTamuning, GuamNo longer taking part
A vizsgálatról
Mit akar kideríteni a vizsgálat
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
A vizsgálat 3 csoportja
- Arm A (platinum doublet, observation)Már használt kezelés, összehasonlításként
INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens based on the treating physician's choice of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. CONTINUANCE THERAPY: Patients then undergo observation. Patients also undergo ECHO as clinically indicated during screening and on the trial. Patients may undergo MRI during screening and as clinically indicated on the trial, as well as CT and blood sample collection throughout the trial. (CLOSED AS OF UPDATE #7)
Kezelés: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Observation Activity, Paclitaxel, Pemetrexed Disodium és Questionnaire Administration
- Arm B (platinum doublet, sequential pembrolizumab)A vizsgált kezelés
INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens\* based on the treating physician's choice of each cycle and pembrolizumab IV over 25-40 minutes on day 1 of each cycle or for cycles 1 and 3 (patients enrolled after 10/14/2020). Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1 of each cycle. Treatment repeats every 21 days for 13 cycles or every 6 weeks for 12 cycles (patients enrolled after 10/14/2020) in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO as clinically indicated during screening and on the trial. Patients may undergo MRI during screening and as clinically indicated on the trial, as well as CT and blood sample collection throughout the trial.
Kezelés: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Pemetrexed Disodium és Questionnaire Administration
- Arm C (platinum doublet, combination pembrolizumab)A vizsgált kezelés
INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens\* based on the treating physician's choice of each cycle and pembrolizumab IV over 25-40 minutes on day 1 of each cycle or for cycles 1 and 3 (patients enrolled after 10/14/2020). Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1 of each cycle. Treatment repeats every 21 days for 13 cycles or every 6 weeks for 12 cycles (patients enrolled after 10/14/2020) in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO as clinically indicated during screening and on the trial. Patients may undergo a MRI during screening and as clinically indicated on the trial, as well as CT and blood sample collection throughout the trial.
Kezelés: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Pemetrexed Disodium és Questionnaire Administration
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
- Publikációk
- Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2026
- Updates on the Perioperative Management of Resectable Non-Small Cell Lung Cancer.Journal of the National Comprehensive Cancer Network : JNCCN, 2026
- PROSPECT-LUNG: A National Clinical Trials Network Trial Advancing Pragmatic Innovation in Cancer Clinical Trials.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2026
- Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).Immunotherapy, 2021
- A regiszteradat frissítve
- 2026. november 12.